5 results about "Xanthosine" patented technology

The invention discloses a non-alcoholic fatty liver biomarker composition and application thereof, and belongs to the technical field of non-alcoholic fatty liver detection. The non-alcoholic fatty liver biomarker composition comprises at least two of citric acid, linoleic acid, L-glutamic acid, L-glycine, asparaginic acid, progesterone, testosterone and uric acid, and further, the hepatic fibrosis biomarker further comprises at least one of 2-hydroxyestradiol, L-citrulline, L-procholecin, N-acetyl-L-methionine and flavin. The biomarker composition is stable, the possibility of misdiagnosis and missed diagnosis of diseases is greatly reduced, and compared with a single omics analysis method, the biomarker composition is more suitable for the occurrence and development mechanism of the diseases.

The invention relates to a gene engineering bacterium for high yield of xanthine nucleoside based on redirected metabolic flux and a construction method and application thereof, and belongs to the technical field of gene engineering. According to the gene engineering bacterium for high yield of xanthine nucleoside based on redirection metabolic flux, E.coli W3110 is used as an original strain, and after transformation, deoD, xapA and purR genes are not expressed; a pur (EKBCSQLFMNHD) gene is subjected to heterologous expression; according to the present invention, guaB, surE, prsA, zwf, ybhE, gnd, rpiA and rpiB genes are subjected to overexpression; replacing a progene promoter of the purA gene with a promoter Pflic; the guaA gene of escherichia coli is not expressed, and the guaA gene regulated and controlled by a promoter Pflic is integrated in an E.coli W3110 genome. The high-yield xanthine nucleoside genetically engineered bacterium based on the redirected metabolic flux, prepared by the invention, takes cheap glucose as a substrate to de novo synthesize the xanthine nucleoside with higher value, has the advantages of stable hereditary performance, no plasmid, no defect and the like, and has a better industrial prospect.

The application relates to the field of biological medicine, and particularly relates to application of xanthine nucleoside in preparation of a drug for preventing and treating acute pancreatitis. In the application, it is found that the xanthine nucleoside can significantly improve pancreas inflammation, necrosis and systemic inflammatory response caused by acute pancreatitis, the xanthine nucleoside is used in preparation of the drug for preventing and treating acute pancreatitis, a new strategy is provided for preventing and treating acute pancreatitis, and the application has a good clinical application prospect.

The invention relates to an antibiotic composition comprising or consisting of: a purine nucleoside selected from guanosine and xanthosine, or a combination thereof; and an inhibitor of thymidine and / or pyrimidine biosynthesis. A further combination with a Beta-lactam antibiotic can be provided. The invention further relates to associated kits, methods and uses in treatment.

The invention discloses a marker related to acute kidney injury related to sepsis. According to the application, the content of Xanthosine in healthy patients, sepsis-related acute kidney injury patients and sepsis-non-acute kidney injury patients is found to have significant difference for the first time, verification of different samples is carried out, and two data sets have relatively high diagnosis efficiency; the discovery of the application provides a new thought for early diagnosis and effective intervention of patients with sepsis-related acute kidney injury, and has a wide application prospect.